首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

2027540

寵物過敏治療市場機會、成長促進因素、產業趨勢分析及預測（2026-2035年）

Pet Allergy Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

出版日期: 2026年04月14日 | 出版商:

Global Market Insights Inc. | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球寵物過敏治療市場預計到 2025 年將價值 23 億美元，預計到 2035 年將以 7.2% 的複合年成長率成長至 46 億美元。

寵物過敏治療市場的擴張主要得益於寵物飼主對早期發現和及時治療重要性的認知不斷提高，以及獸醫服務的可及性日益改善。獸醫學的進步，特別是治療方法的創新和診斷準確性的提高，不斷提升治療效果，並加速了各種治療方法的普及。寵物過敏治療旨在控制和緩解影響動物的各種過敏症狀。這些解決方案包括多種藥物和治療方法，旨在改善寵物的健康和生活品質。隨著寵物飼主對未治療過敏的長期健康影響有了更深入的了解，對有效治療方法的需求顯著增加。市場也正朝著長期照護解決方案的方向發展，而創新治療方法正受到越來越多的關注。預防醫學意識的持續提高進一步增強了產品的接受度，並支持市場的永續成長。對獸醫基礎設施和產品研發投入的增加也促進了寵物過敏治療市場的整體擴張。

市場範圍
開始年份	2025
預測期	2026-2035
起始金額	23億美元
預測金額	46億美元
複合年成長率	7.2%

預計到2025年，抗組織胺市場規模將達到8.045億美元。其市場主導地位主要歸功於抗組織胺作為動物過敏性疾病的主要治療選擇而廣泛應用。這些藥物因其快速緩解症狀和良好的安全性而備受推崇。多種給藥途徑和劑型進一步推動了強勁的市場需求。這些能夠有效應對輕度至中度過敏反應的治療方法，大大促進了其持續應用和商業性成功。

預計到2025年，犬類市場將佔據65%的市場。此細分市場的成長主要得益於人們對犬類作為伴侶動物的需求不斷成長以及犬類醫療保健支出的增加。寵物擁有率的上升和人們對動物健康意識的增強是推動這一趨勢的主要因素。犬類過敏性疾病發生率的上升進一步加速了對專業治療方法的需求。此外，經濟狀況的改善以及更先進、更具針對性的產品的普及預計將在整個預測期內持續支持該細分市場的擴張。

預計到2025年，北美寵物過敏治療市場將佔據41.8%的市場佔有率，並在2035年之前以6.8%的複合年成長率成長。該地區憑藉其高寵物擁有率和日益成長的寵物福利意識，保持著強勁的市場地位。高額的獸醫護理支出以及行業領導者的存在，都鞏固了該地區的市場主導地位。對先進治療方案的早期應用以及人們對寵物健康的高度重視，進一步推動了該地區的成長。完善的獸醫生態系統以及寵物醫療服務的廣泛認可，持續鞏固北美在該市場的領先地位。

產業生態系分析
影響產業的因素
- 成長促進因素
  - 寵物過敏的盛行率正在上升。
  - 非處方藥的供應情況
  - 寵物數量增加和獸醫醫療費用增加
  - 獸醫皮膚科進展
- 產業潛在風險與挑戰
  - 藥物的副作用
  - 自然療法和家庭療法的傳播
- 市場機遇
  - 新興市場的擴張
  - 個性化醫療的發展
監理情勢
- 北美洲
  - 美國
  - 加拿大
- 歐洲
- 亞太地區
科技與創新趨勢
- 目前技術
- 新興技術
管道分析（基於初步調查）
價格分析（基於初步調查）
未來市場趨勢
人工智慧和生成式人工智慧對市場的影響
波特的分析
PESTEL 分析

第4章競爭情勢

介紹
企業市佔率分析
企業矩陣分析
主要市場公司的競爭分析
競爭定位矩陣
主要進展
- 併購
- 夥伴關係與合作
- 新產品發布
- 業務拓展計劃

第5章市場估計與預測：依藥物類別分類，2022-2035年

抗組織胺藥
皮質類固醇
免疫療法
其他藥物分類

第6章市場估價與預測：依寵物類型分類，2022-2035年

狗
貓
兔子
其他寵物類型

第7章市場估計與預測：依給藥途徑分類，2022-2035年

口服
腸外
外用

第8章市場估算與預測：依通路分類，2022-2035年

獸藥
零售藥房
網路藥房

第9章市場估計與預測：依地區分類，2022-2035年

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第10章：公司簡介

Antech Diagnostics
Boehringer Ingelheim International
Ceva Sante Animale
Dechra
Elanco
IDEXX Laboratories
Merck Animal Health
Neogen Corporation
Nextmune
PetIQ
Provetica
Vetoquinol
Virbac
Zoetis

簡介目錄

Product Code: 13824

The Global Pet Allergy Treatment Market was valued at USD 2.3 billion in 2025 and is estimated to grow at a CAGR of 7.2% to reach USD 4.6 billion by 2035.

Market expansion is supported by increasing awareness among pet owners regarding early detection and timely treatment, along with improved access to veterinary care. Advancements in veterinary science, particularly in treatment innovation and diagnostic accuracy, continue to enhance therapeutic outcomes and drive adoption. Pet allergy treatments are designed to manage and control a broad range of allergic conditions affecting animals. These solutions include various pharmaceutical and therapeutic approaches aimed at improving pet health and quality of life. Growing understanding among pet owners about the long-term health implications of untreated allergies has significantly increased demand for effective treatment options. The market is also witnessing a shift toward long-term care solutions, with innovative therapies gaining traction. Preventive healthcare awareness continues to rise, further strengthening product acceptance and supporting sustained market growth. Increasing investments in veterinary healthcare infrastructure and product development are also contributing to the overall expansion of the pet allergy treatment market.

Market Scope
Start Year	2025
Forecast Year	2026-2035
Start Value	$2.3 Billion
Forecast Value	$4.6 Billion
CAGR	7.2%

The antihistamines segment captured USD 804.5 million in 2025. This dominance is driven by their widespread adoption as a primary treatment option for allergic conditions in animals. These medications are frequently recommended due to their effectiveness in providing quick symptom relief and their favorable safety profile. Their versatility in administration and accessibility across various formats further supports strong market demand. The ability of these treatments to address mild to moderate allergic responses contributes significantly to their continued usage and commercial success.

The dogs segment held a 65% share in 2025. Growth in this segment is fueled by the increasing preference for dogs as companion animals and rising spending on their healthcare. Higher pet ownership rates, combined with greater awareness of animal health, are key contributors to this trend. The growing incidence of allergic conditions among dogs further accelerates demand for specialized treatments. Additionally, improving economic conditions and the availability of advanced, targeted products continue to support segment expansion over the forecast period.

North America Pet Allergy Treatment Market represents 41.8% share in 2025 and is expected to grow at a CAGR of 6.8% through 2035. The region maintains a strong position due to high levels of pet ownership and increasing emphasis on pet well-being. Significant expenditure on veterinary healthcare and the presence of leading industry participants contribute to market dominance. Early adoption of advanced treatment solutions and strong awareness regarding pet health conditions further drive regional growth. A well-developed veterinary ecosystem, along with widespread acceptance of pet healthcare services, continues to reinforce North America's leadership in the market.

Key companies operating in the Pet Allergy Treatment Market include Antech Diagnostics, Boehringer Ingelheim International, Ceva Sante Animale, Dechra, Elanco, IDEXX Laboratories, Merck Animal Health, Neogen Corporation, Nextmune, PetIQ, Provetica, Vetoquinol, Virbac, and Zoetis. Companies in the Pet Allergy Treatment Market are actively enhancing their market position through continuous innovation and strategic expansion initiatives. They focus on developing advanced therapeutic solutions that improve treatment effectiveness and long-term outcomes. Investment in research and development remains a priority to introduce novel products and improve diagnostic capabilities. Strategic collaborations and partnerships enable companies to broaden their geographic presence and strengthen distribution networks. Businesses are also emphasizing digital integration and data-driven veterinary solutions to enhance service delivery. Expansion of production capabilities and localized manufacturing helps improve supply efficiency. Additionally, companies are focusing on customer engagement, education, and preventive care awareness to build brand loyalty and sustain long-term growth.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research approach
1.3 Quality commitments
- 1.3.1 GMI AI policy and data integrity commitment
  - 1.3.1.1 Source consistency protocol
1.4 Research trail and confidence scoring
- 1.4.1 Research trail components
- 1.4.2 Scoring components
1.5 Data collection
- 1.5.1 Partial list of primary sources
1.6 Data mining sources
- 1.6.1 Paid sources
  - 1.6.1.1 Sources, by region
1.7 Base estimates and calculations
- 1.7.1 Revenue share analysis
- 1.7.2 Base year calculation
1.8 Forecast model
1.9 Research transparency addendum
- 1.9.1 Source attribution framework
- 1.9.2 Quality assurance metrics
- 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360° synopsis
2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Drug class trends
- 2.2.3 Pet type trends
- 2.2.4 Route of administration trends
- 2.2.5 Distribution channel trends
2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of pet allergies
  - 3.2.1.2 Availability of over-the-counter (OTC) medications
  - 3.2.1.3 Increasing pet ownership and rising veterinary expenditures
  - 3.2.1.4 Advancements in veterinary dermatology
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects of medications
  - 3.2.2.2 Increasing adoption of natural or home-based remedies
- 3.2.3 Market opportunities
  - 3.2.3.1 Expansion in emerging markets
  - 3.2.3.2 Development of personalized treatments
3.3 Regulatory landscape
- 3.3.1 North America
  - 3.3.1.1 U.S.
  - 3.3.1.2 Canada
- 3.3.2 Europe
- 3.3.3 Asia Pacific
3.4 Technology/innovation landscape
- 3.4.1 Current technologies
- 3.4.2 Emerging technologies
3.5 Pipeline analysis (Driven by Primary Research)
3.6 Pricing analysis (Driven by Primary Research)
3.7 Future market trends
3.8 Impact of AI & generative AI on the market
3.9 Porter’s analysis
3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

5.1 Key trends
5.2 Antihistamines
5.3 Corticosteroids
5.4 Immunotherapy
5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Pet Type, 2022 - 2035 ($ Mn)

6.1 Key trends
6.2 Dogs
6.3 Cats
6.4 Rabbits
6.5 Other pet types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Topical

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

8.1 Key trends
8.2 Veterinary hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE